Evidence map›Paper›PMID 26291313›Full record

ArticleCell death & disease2015

Autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma modulates proliferation and differentiation.

M Sun, F Huang, D Yu, Y Zhang, H Xu, L Zhang, L Li, L Dong, L Guo, S Wang

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Role of SPRY4 in health and disease.Frontiers in oncology · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

M SunLaboratory Animal Research Center, Soochow University School of Medicine, Suzhou 215123, China.
F HuangDepartment of Pathology, Soochow University School of Medicine, Suzhou 215123, China.
D YuDepartment of Plastic Surgery, Second Affiliated Hospital, Soochow University, Suzhou 215004, China.
Y ZhangDepartment of Pathology, Soochow University School of Medicine, Suzhou 215123, China.
H XuDepartment of Oncology, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
L ZhangDepartment of Surgery, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
L LiDepartment of Osteology, Second Affiliated Hospital, Soochow University, Suzhou 215004, China.
L DongDepartment of Pathology, Soochow University School of Medicine, Suzhou 215123, China.
L GuoDepartment of Pathology, Soochow University School of Medicine, Suzhou 215123, China.
S WangDepartment of Pathology, Soochow University School of Medicine, Suzhou 215123, China.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CNSecond Affiliated Hospital of Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The origin of rhabdomyosarcoma (RMS) remains controversial. However, specific microRNAs (miRNAs) are downregulated in RMS and it is possible that re-expression of these miRNAs may lead to differentiation. Transforming growth factor-β1 (TGF-β1) is known to block differentiation of RMS. We therefore analyzed miRNA microarrays of RMS cell lines with or without TGF-β1 knockdown and identified a novel anti-oncogene miR-411-5p. Re-expression of miR-411-5p inhibited RMS cell proliferation in vitro and tumorigenicity in vivo. Using a luciferase reporting system and sequence analysis, the potential target of miR-411-5p was identified as sprouty homolog 4 (SPRY4), which inhibits protein kinase Cα-mediated activation of mitogen-activated protein kinases (MAPKs), especially p38MAPK phosphorylation. These results revealed an inverse correlation between TGF-β1/SPRY4 and miR-411-5p levels. SPRY4 small interfering RNA and miR-411-5p both activated p38MAPK phosphorylation and also promoted apoptosis and myogenic differentiation, indicated by increased caspase-3, myosin heavy chain, and myosin expression. SPRY4 and miR-411 mRNA levels correlated with TGF-β1 expression levels in RMS tissues, which was confirmed by immunohistochemical staining for TGF-β1, SPRY4, and phosphorylated p38MAPK proteins. Overall, these results indicate that miR-411-5p acts as an RMS differentiation-inducing miRNA prompting p38MAPK activation via directly downregulating SPRY4. These results establish an autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK in RMS, which governs the switch between proliferation and differentiation.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCell DifferentiationCell Line, TumorCell ProliferationFeedback, PhysiologicalGenes, ReporterHumansLuciferasesMiceMice, Inbred BALB CMice, NudeMicroRNAsNeoplasm TransplantationNerve Tissue ProteinsOligonucleotide Array Sequence AnalysisLuciferasesMicroRNAsNerve Tissue Proteinsp38 Mitogen-Activated Protein KinasesProtein Kinase C-alphaSpry4 protein, mouseTransforming Growth Factor beta1

Identifiers

PMID26291313
PMCPMC4558514
OpenAlexW1888318789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.